肽微陣列市場 - 成長，趨勢，COVID-19的影響，及預測 (2021∼2026 年)
Peptide Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1005813|
|出版日期||內容資訊||英文 115 Pages
|肽微陣列市場 - 成長，趨勢，COVID-19的影響，及預測 (2021∼2026 年) Peptide Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年04月21日||內容資訊: 英文 115 Pages||
在 2020 年 10 月發表在Journal of Proteins and Proteomics上的一篇文章中，研究人員強調，蛋白質組技術的發展不僅將加快解決冠狀病毒大流行的進程，還將有助於應對當前的 COVID-19 危機。
The Peptide Microarray Market is expected to register a CAGR of 5% during the forecast period.
Peptide microarrays and protein, the emerging tools for clinical assays and proteomics, are high-throughput methods that decide the function of proteins on a large scale. The development of therapeutics requires an accurate understanding of the role in the SARS-CoV-2 infection process and progression of COVID-19. The field of proteomics is equipped with the technologies that are required to help face this challenge.
In an article published in October 2020 in the Journal of Proteins and Proteomics, researchers have highlighted that developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemics but will also help to tackle the current COVID-19 crisis.
A Peptide Microarray is used to study the binding properties of protein-protein interaction that comprises thousands of peptides in distinct pattern that will be used as a high throughput screening tool in biomedical science.
Therefore the increasing burden of cancer and technological advancement are the major factors that are driving the studied market globally. Moreover, the rising prevalence of chronic diseases will further contribute to the peptide microarray market. For instance, according to the National Centre for Chronic Disease Prevention and Health Promotion (NCCDPHP), the United States has a population of about 330 million in which 6 in 10 adults have chronic diseases each year. Thus, promoting diagnosis testing will propel the peptide microarray market.
Furthermore, rising molecular-based diagnostics techniques demand with the advancement in the technology of diagnostic testing dominant the peptide microarray market.
Instrument Segment is Expected to Hold a Major Market Share in the Peptide Microarray Market
The instrument segment is expected to witness good growth in the market and is anticipated to show a similar trend over the forecast period owing to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious disease. For instance, PEPperPRIINT offers PEPperCHIP Standard Peptide Microarrays which cover epitopes, antigens, and viral proteomics and being widely used in various types of research (allergen, cancer, signature discovery).
Moreover, these are also used for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation for protein interaction. For instance, JPT Peptide Technologies has a product PepStar Peptide Microarrays which helps in enzyme profiling and identifies a substrate for orphan enzymes.
The research and development of peptide products are increasing as they are cost-effective, efficient, and have lower toxicity. These peptides play a major part in the COVID-19 related research. In 2020, PEPperPRINT launched coronavirus research product PEPperCHIP Pan-Corona Spike Protein Microarray, which will give researchers access to serologically screen human coronavirus spike proteins in one assay. Hence, these factors will fuel the growth of studied market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the global Peptide Microarray market due to increasing healthcare expenditure and the presence of well developed healthcare infrastructure. For instance, a report was published in July 2019 by MDPI where in zika virus disease infected several territories in North America in which research has been carried out by using a peptide microarray to find the best candidates for T-B cells epitopes by immunoinformatic approach.
The growing chronic disease complexities are expected to enhance the demand for early diagnosis of disease in the hospitals, thereby, increasing the use of diagnostic capabilities. Thus, expected to boost the usage of peptide microarray. According to Globocan 2020, the estimated incidence of new cancer cases was 2,281,658, and the number of deaths was 612,390 due to cancer in 2020, in the United States. The most common cancers in the United States were breast, lung, prostate, and colon (101,809). The high cancer burden will surge the demand for peptide microarray.
Moreover, rising molecular-based diagnostic technique and increasing awareness among population is also fueling the growth of the overall regional market.
Some of the companies which are currently dominating the market are Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc and Arrayit Corporation, among others.
The market players are expanding their market position by adopting various strategies such as acquisitions and mergers, research collaboration, while several others are introducing new products to grow their presence in the market. For instance, in 2020, JPT peptide technologies accelerated the development of a broad collection of SARS-CoV-2 PepMix Peptide Pools that will span the most relevant antigens to address cellular immunity. JPT developed a Pan-Coronavirus RepliTope Peptide Microarray spanning the entire SARS-CoV-2 proteome and selected antigens of MERS-CoV, Common Cold Coronaviruses, and SARS-CoV for profiling humoral immune responses.